Logotype for Jubilant Ingrevia Limited

Jubilant Ingrevia (JUBLINGREA) Q1 26/27 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Jubilant Ingrevia Limited

Q1 26/27 earnings summary

23 Jul, 2026

Executive summary

  • Q1 FY27 delivered strong financial performance with consolidated revenue reaching ₹1,300 crore, up 25% year-over-year, and EBITDA up 37% year-over-year, marking a 15-quarter high and robust operational execution despite global supply chain disruptions.

  • Growth was broad-based across Specialty Chemicals, Nutrition, and Chemical Intermediates, with Pharmaceuticals and Agrochemicals showing resilient demand and healthy export visibility.

  • The company advanced strategic priorities, expanding its CDMO and fine chemicals pipeline, completed the integration of Remidex Pharma, and maintained global leadership in core products.

  • Net profit for the quarter was ₹10,582 lakhs, up from ₹7,510 lakhs year-over-year and ₹8,644 lakhs sequentially.

  • The company expanded its customer base, especially in electronics/semiconductor and cosmetics.

Financial highlights

  • Revenue reached ₹1,300 crore, up 25% year-over-year and 10% sequentially; EBITDA at ₹209 crore, up 37% year-over-year and 22% quarter-on-quarter; PAT at ₹106 crore, up 41% year-over-year and 22% quarter-on-quarter.

  • Specialty Chemicals revenue was ₹533 crore (+11% YoY), Nutrition & Health revenue ₹243 crore (+36% YoY), Chemical Intermediates revenue ₹524 crore (+38% YoY).

  • EBITDA margin improved to 16%, PAT margin at 8%, and EPS was ₹6.7, up 41% YoY.

  • Operating margin was 11.39% (up from 9.76% YoY); net profit margin improved to 8.07% from 7.16% YoY.

  • Debt service coverage ratio stood at 4.81 times, and interest service coverage ratio at 12.01 times.

Outlook and guidance

  • Sequential improvement in revenue and EBITDA expected in coming quarters, led by Specialty Chemicals and Nutrition, with recovery in acetyls.

  • FY27 EBITDA guidance maintained at ₹750–800 crore, with first half expected to deliver ₹400+ crore.

  • New multipurpose plant on track for commissioning by year-end, supporting CDMO and fine chemicals growth.

  • The group is monitoring the impact of the newly notified Code of Wages (Central) Rules, 2026, and will update accounting as needed.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more